title: Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans.
abstract: BACKGROUND
  The vein of Marshall (VOM) is an attractive target during ablation of atrial fibrillation due to its autonomic innervation, its location anterior to the left pulmonary veins and drainage in the coronary sinus.
  
  
  RESULTS
  We studied 17 dogs. A coronary sinus venogram showed a VOM in 13, which was successfully cannulated with an angioplasty wire and balloon. In 5 dogs, electroanatomical maps of the left atrium were performed at baseline and after ethanol infusion in the VOM, which demonstrated a new crescent-shaped scar, extending from the annular left atrium towards the posterior wall and left pulmonary veins. In 4 other dogs, effective refractory periods (ERP) were measured at 3 sites in the left atrium, before and after high-frequency bilateral vagal stimulation. The ERP decreased from 113.6+/-35.0 ms to 82.2+/-25.4 ms (p<0.05) after vagal stimulation. After VOM ethanol infusion, vagally-mediated ERP decrease was eliminated (from 108.6+/-24.1 ms to 96.4 +/-16.9ms, p=NS). The abolition of vagal effects was limited to sites near the VOM (ERP: 104+/-14 ms, vs 98.6+/-12.2 ms post vagal stimulation, p=ns), as opposed to sites remote to VOM (ERP: 107.2+/-14.9 ms, vs 78.6+/-14.7ms post vagal stimulation, p<0.05). To test feasibility in humans, 5 patients undergoing pulmonary vein antral isolation had successful VOM cannulation and ethanol infusion: left atrial voltage maps demonstrated new scar involving the infero-posterior left atrial wall extending towards the left pulmonary veins.
  
  
  CONCLUSIONS
  Ethanol infusion in then VOM achieves significant left atrial tissue ablation, abolishes local vagal responses and is feasible in humans.
authors.affiliation: Methodist Hospital Research Institute and the Division of Cardiac Electrophysiology, Department of Cardiology, The Methodist Hospital, Houston, Texas 77030, USA. mvalderrabano@tmhs.org
authors.forename: Miguel
authors.initials: M
authors.lastname: Valderrábano
authors.forename: Harvey R
authors.initials: HR
authors.lastname: Chen
authors.forename: Jasvinder
authors.initials: J
authors.lastname: Sidhu
authors.forename: Liyun
authors.initials: L
authors.lastname: Rao
authors.forename: Yuesheng
authors.initials: Y
authors.lastname: Ling
authors.forename: Dirar S
authors.initials: DS
authors.lastname: Khoury
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D002921:Cicatrix; D017023:Coronary Angiography / Q000379:methods; D003331:Coronary Vessels / Q000196:embryology; D004285:Dogs; D000431:Ethanol / Q000008:administration & dosage*; D005240:Feasibility Studies; D006325:Heart Atria / Q000294:innervation / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D010690:Phlebography; D016896:Treatment Outcome; D014628:Vagotomy / Q000379:methods*; D014683:Vena Cava, Superior / Q000196:embryology
chemical_list: D000431:Ethanol